Telo Genomics Corp
TSXV:TELOView on OTCQB

  • LAST PRICE
    0.1100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.1250/ 11
  • Ask / Lots
    0.1300/ 31
  • Open / Previous Close
    --- / 0.1100
  • Day Range
    ---
  • 52 Week Range
    0.1050
    0.2300
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 19, 2024

      Show headlines and story abstract

    • 2:00PM ET on Tuesday Nov 19, 2024 by MT Newswires
      Companies Mentioned: TELO
      02:00 PM EST, 11/19/2024 (MT Newswires) -- Telo Genomics (TELO.V), which is developing a telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, says its application to the IPON program (In...

    • 8:46AM ET on Tuesday Nov 19, 2024 by Newsfile
      Companies Mentioned: TDSGF

      Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that its application to the IPON program (Intellectual Property Ontario) was approved. The IPON program leverages the innovation of Ontario enterprises in securing and expanding their intellectual property (IP) portfolio. The program provides training, advisory services and financial support. Within the program Telo may receive up to CAD 80,000 of reimbursement for its prospective IP costs in addition to strategic input and guidance.

    • 8:46AM ET on Tuesday Nov 19, 2024 by Dow Jones
      Companies Mentioned: TELO

      Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that its application to the IPON program (Intellectual Property Ontario) was approved. The IPON program leverages the innovation of Ontario enterprises in securing and expanding their intellectual property (IP) portfolio. The program provides training, advisory services and financial support. Within the program Telo may receive up to CAD 80,000 of reimbursement for its prospective IP costs in addition to strategic input and guidance.

  • Oct 30, 2024

      Show headlines and story abstract

    • 8:47AM ET on Wednesday Oct 30, 2024 by Dow Jones
      Companies Mentioned: TELO

      Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has amended its agreement with Mayo Clinic, Rochester, Minnesota, US. The amendment is an extension of the Telo Genomics relationship with Mayo Clinic to include their participation in Telo's Physician Experience Program SMART, using the Company's TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients. SMM is a precursor to active multiple myeloma.

    • 8:46AM ET on Wednesday Oct 30, 2024 by Newsfile
      Companies Mentioned: TDSGF

      Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has amended its agreement with Mayo Clinic, Rochester, Minnesota, US. The amendment is an extension of the Telo Genomics relationship with Mayo Clinic to include their participation in Telo's Physician Experience Program SMART, using the Company's TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients. SMM is a precursor to active multiple myeloma.

Peers Headlines